Merck Kgaa · XETR:MRK
Merck Kgaa — FY2024 Earnings Presentation
14 slides from Merck Kgaa's earnings presentation, 2025
Slide 1: Full-year 2024 Results: Merck delivers profitable growth
Full-year 2024 Results Merck delivers profitable growth
Slide 2: 2024: Merck returns to profitable growth, delivers on guidance
1 2024: Merck returns to profitable growth, delivers on guidance. 2 Q4: Strong performance across all business sectors. 3 2025 outlook: Confident in continued profitable growth.
Slide 3: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other wor
Slide 4: Merck Group – Guidance delivered
Merck Group – Guidance delivered 2024 Guidance 2024 Results Net sales €20.7 – 22.1 bn €21.2 bn Guidance: achieved Commitment met: return to profitable EBITDA pre €5.8 – 6.4 bn €6.1 bn growth in 2024 Resilience of multi- industry business EPS pre €8.20 – 9.30 €8.63 model demonstrated 4 Merck Q4
Slide 5: Highlights: Strong finish to 2024 with outstanding profitable growth
Highlights: Strong finish to 2024 with outstanding profitable growth Operations Group Financials Q4 YoY organic sales growth1 Life Science: Sales growing +2%, with solid QoQ growth (+4%) PS sales growth +4% YoY and +5% QoQ; SLS up +3% Q4 organic sales: +3.8% Very strong YoY and low-teens QoQ i
Slide 6: Financial Overview
cy * 7 “ties = a - e, > +. €EMANTIAL. . “? * : ae overview »
Slide 7: FY 2024: Overview
FY 2024: Overview Key figures Comments [€m] FY 2023 FY 2024 Δ Sales up +1% with organic growth overcompensating FX headwinds Net sales 20,993 21,156 0.8% Strong sales growth from HC and EL EBITDA pre 5,879 6,072 3.3% partially compensated by moderate sales Margin (in % of net sales) 28.0% 28.7%
Slide 8: Life Science: Leaving destocking behind in 2024 with H2 growth inflection
Life Science: Leaving destocking behind in 2024 with H2 growth inflection Business performance Sector focus H2 growth inflection in PS (sales +4% org.), Reaccelerating towards mid-term growth leaving customer destocking behind targets in 2025 Organic sales down -3% with Science & Lab Driven
Slide 9: Healthcare: Strong growth in CM&E and Oncology drive sector growth
Healthcare: Strong growth in CM&E and Oncology drive sector growth significantly above mid-term ambition Business performance Sector focus Strong sales growth, stringent cost focus and Strong confidence in long-term growth led transitorily lower R&D drive significant EBITDA by internal and exter
Slide 10: Electronics: Profitable growth in Semiconductor Solutions driven by AI
Electronics: Profitable growth in Semiconductor Solutions driven by AI and advanced node technologies Business performance Sector focus Semiconductor Solutions sales up +8% org; Short-term industry outlook now ~80%1 of segment sales excl. Surface Continued growth in materials needed for AI and
Slide 11: Outlook & Guidance
ie Pr | bes, “3 ipance —.... er Ps e *@ *« . ¢ bad . @ MARR
Slide 12: Merck Group Full-year 2025 guidance
Merck Group Full-year 2025 guidance Net sales: Organic: +3% to +6% YoY FX: -1% to +2% YoY ~€21.5 – €22.9 bn EBITDA pre: Organic: +3% to +8% YoY FX: -2% to +1% YoY ~€6.1 – €6.6 bn 12 Merck Q4 2024 Results Presentation | March 6, 2025
Slide 13: 2025 business sector guidance
2025 business sector guidance1 Net sales EBITDA pre Life Science Organic: +2% to +7% YoY Organic:+2% to +9% YoY FX: 0% to +3% YoY FX: -1% to +2% YoY ~€9.1 bn to €9.8 bn ~€2.6 bn to €2.9 bn Net sales EBITDA pre Healthcare Organic: +1% to +5% YoY Organic:+3% to +9% YoY FX: -2% to +1%
Slide 14: 2024: Merck returns to profitable growth, delivers on guidance
1 2024: Merck returns to profitable growth, delivers on guidance. 2 Q4: Strong performance across all business sectors. 3 2025 outlook: Confident in continued profitable growth.